Latest News
From the Journals
A new long COVID explanation: Low serotonin levels?
The study found lower serotonin levels in long COVID patients, compared with patients who were diagnosed with acute COVID-19 but who fully...
Hitting a Nerve
The placebo effect
Conference Coverage
Duchenne muscular dystrophy gene therapy safe, effective at 4 years
“What’s really striking, and in my mind the most impressive, is that when you follow these patients out 3 or 4 years ... you see there is this...
Feature
Second infection hikes long COVID risk: Expert Q&A
There are people who think, “This is a nothing-burger anymore,” or “It’s not an issue anymore.” It’s still happening with the current variants.
Conference Coverage
Enhanced natural killer cell therapy shows promise in Alzheimer’s
A phase 1 proof-of-concept trial showed that natural killer cell therapy reduced both amyloid and tau proteins and dramatically reduced the...
Latest News
Patient contact time vs. admin: Is your contract fair?
“It’s important for employers to recognize that seeing patients isn’t the only thing a doctor does and there’s a lot of work in addition to face-...
Conference Coverage
Genetic therapies bring change to neurology clinics
Advancements are set to alter the approach to some patients and inspire a demand for genetic counselors in neuromuscular clinics.
From the Journals
People with long COVID don’t show signs of brain damage
“The findings thus suggest that post-COVID condition is not the result of ongoing infection, immune activation, or brain damage.”
From the Journals
AF tied to 45% increase in mild cognitive impairment
The data suggest combining anticoagulation and symptom and comorbidity management may prevent cognitive deterioration.
From the Journals
Be advised: Thyroid hormones may increase risk of cognitive disorders in older adults
“We are finding more and more complications from overtreatment rather than benefit in this population.”
Conference Coverage
In myasthenia gravis, antibodies pass open-label tests
New class of therapies interfere with IgG recycling and have similar efficacy across multiple cycles of treatment.